表柔比星注射液联合顺铂注射液治疗晚期耐药性子宫内膜癌的临床研究

发布时间：2018-01-13 21:01

本文关键词：表柔比星注射液联合顺铂注射液治疗晚期耐药性子宫内膜癌的临床研究　出处：《中国临床药理学杂志》2017年05期 　论文类型：期刊论文

【摘要】：目的观察表柔比星注射液联合顺铂注射液治疗晚期耐药性子宫内膜癌的临床疗效及安全性。方法将56例晚期耐药性子宫内膜癌患者随机分为对照组28例与试验组28例。对照组予以顺铂30 mg·m-2,第1,8天,静脉滴注+氟尿嘧啶650 mg·m-2,第1,8天,静脉滴注;试验组予以顺铂30 mg·m-2,第1,8天,静脉滴注+表柔比星40 mg·m-2,第1天,静脉滴注。2组患者一个疗程均为4周,共治疗2个疗程。比较2组患者的临床疗效、卵巢癌抗原(CA125)、附睾蛋白4(HE4)、脂联素(APN)以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为85.71%(24/28例)和60.71%(17/28例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的CA125分别为(28.62±0.33),(40.52±0.45)U·L~(-1);HE4分别为(1.57±0.24),(35.93±0.38)pmol·L~(-1);APN分别为(8.59±0.98),(7.74±0.78)μg·m L~(-1),差异均有统计学意义(P0.05)。试验组的药物不良反应主要有脱发、口腔黏膜炎、恶心呕吐、腹泻和白细胞减少,对照组的药物不良反应主要有脱发、食欲缺乏、恶心呕吐、白细胞减少、血小板减少和蛋白尿。试验组和对照组的药物不良反应发生率分别为21.43%和32.14%,差异无统计学意义(P0.05)。结论表柔比星注射液联合顺铂注射液治疗晚期耐药性子宫内膜癌的临床疗效显著,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of epirubicin injection combined with cisplatin injection in the treatment of advanced drug-resistant endometrial carcinoma. Methods 56 patients with advanced drug-resistant endometrial carcinoma were randomly divided into control group (n = 28) and trial group (n = 28). The control group was treated with cisplatin 30. Mg 路m-2. On the 1st day, 650mg 路m -2 fluorouracil was injected intravenously, and on the 1st day, 650mg 路m -2 was injected intravenously. The experimental group was given cisplatin 30 mg 路m ~ (-2), day 1 8, epirubicin 40 mg 路m ~ (-2). On day 1, the course of treatment in group 2 was 4 weeks. To compare the clinical efficacy of the two groups, ovarian cancer antigen CA125, epididymal protein 4 (HE4). Adiponectin (APN) and adverse drug reactions. Results after treatment. The total effective rates of the test group and the control group were 85.71 / 24 / 28 and 60.71 / 17 / 28, respectively. The difference was statistically significant (P 0.05). The CA125 of the experimental group and the control group were 40.52 卤0.45 U 路L ~ (-1) and 28.62 卤0.33 U 路L ~ (-1), respectively. HE4 was 1.57 卤0.24, respectively. The HE4 was 35.93 卤0.38 pmol 路L ~ (-1). APN was 8.59 卤0.98 渭 g 路mL ~ (-1), respectively (7.74 卤0.78) 渭 g 路mL ~ (-1). The main adverse drug reactions in the test group were alopecia, oral mucositis, nausea and vomiting, diarrhea and leukopenia, while the adverse drug reactions in the control group were alopecia. Appetite deficiency, nausea and vomiting, leukopenia, thrombocytopenia and proteinuria. The incidence of adverse drug reactions in the trial group and control group was 21.43% and 32.14%, respectively. Conclusion the clinical efficacy of epirubicin injection combined with cisplatin injection in the treatment of advanced drug-resistant endometrial carcinoma is significant and the incidence of adverse drug reactions is not increased.
【作者单位】：浙江大学医学院附属妇产科医院妇产科;衢州市人民医院妇产科;
【基金】：浙江省医药卫生计划基金资助项目(2011ZDA015)
【分类号】：R737.33
【正文快照】： (1.浙江大学医学院附属妇产科医院妇产科,杭州310000;2.衢州市人民医院妇产科,浙江衢州324300)FAN Su-hong1,2,LIN Jun1,MA Jun-yan1(1.Department of Gynecology,TheAffiliated Obstetrics and GynecologyHospital of Zhejiang University MedicalCollege,Hangzhou 310000,Ch

【相似文献】